Efficacy and Safety of Cyclophosphamide in Treatment of Myasthenia Gravis in Children with Thymus Adenoma of Different Malignant Degree
OBJECTIVE: To probe into the efficacy and safety of cyclophosphamide in treatment of myasthenia gravis in children with thymus adenoma of different malignant degree. METHODS: Totally 84 cases of myasthenia gravis in children with thymus adenoma of different malignant degree admitted into Children's Hospital Affiliated to Zhengzhou University from Jan. 2010 to Jan.2018 were extracted as the research objects. Children with myasthenia gravis with low malignant degree of thymoma were included as the control group (n=42), and children with myasthenia gravis with high malignant degree of thymoma were included as the observation group (n=42). Both groups were treated with cyclophosphamide. The clinical absolute scores of myasthenia gravis, clinical efficacy and the incidence of adverse drug reactions were compared between two groups. RESULTS: After treatment, the absolute clinical scores of myasthenia gravis in the observation group and the control group were (7.33±1.04) and (7.28±0.98) points, respectively, which were lower than those before treatment, and the difference was statistically significant (P<0.05), but the difference between the two groups was not statistically significant (P>0.05). The total effective rate in the observation group was 85.71% (36/42), significantly higher than that in the control group (64.29%, 27/42), with statistically significant difference (P<0.05). During the treatment, the incidence of adverse drug reactions in the observation group and the control group were 11.90% (5/42) and 9.52% (4/42), respectively, with statistically significant differences (P>0.05). CONCLUSIONS: Cyclophosphamide is more effective in treatment of myasthenia gravis in children with thymus adenoma of higher malignant degree, and the safety is higher.